Deal completion sees Plexxikon become part of Daiichi Sankyo

Following US antitrust clearance, Daiichi Sankyo has completed its acquisition of Plexxikon, successfully sealing a $935 million transaction that will see the formerly private US firm continuing to operate as an independent R&D unit of the Japanese major.

More from Anticancer

More from Therapeutic Category